Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us
International Journal of Molecular Sciences · 13.04.2023 · 24 (8) · 7233
DOI: 10.3390/ijms24087233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.04.2023. Verfasst von Santosh Kumar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Ariel University, Ariel 40700, Israel. Hauptthemen laut MEDLINE: Camptothecin, Antineoplastic Agents. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Israel Science Foundation.
Abstract (Originalsprache)
Irinotecan (SN-38) is a potent and broad-spectrum anticancer drug that targets DNA topoisomerase I (Top1). It exerts its cytotoxic effects by binding to the Top1-DNA complex and preventing the re-ligation of the DNA strand, leading to the formation of lethal DNA breaks. Following the initial response to irinotecan, secondary resistance is acquired relatively rapidly, compromising its efficacy. There are several mechanisms contributing to the resistance, which affect the irinotecan metabolism or the target protein. In addition, we have demonstrated a major resistance mechanism associated with the elimination of hundreds of thousands of Top1 binding sites on DNA that can arise from the repair of prior Top1-dependent DNA cleavages. Here, we outline the major mechanisms of irinotecan resistance and highlight recent advancements in the field. We discuss the impact of resistance mechanisms on clinical outcomes and the potential strategies to overcome resistance to irinotecan. The elucidation of the underlying mechanisms of irinotecan resistance can provide valuable insights for the development of effective therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, Ariel University, Ariel 40700, Israel.
ORCID-Profile: Santosh Kumar, Michael Y Sherman
Förderung
- NIH HHS
- Israel Science Foundation
Zitieren
APA
Kumar, S., & Sherman, M. Y. (2023). Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us. International Journal of Molecular Sciences, 24(8), 7233. https://doi.org/10.3390/ijms24087233
Vancouver
Kumar S, Sherman MY. Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us. International Journal of Molecular Sciences. 2023;24(8):7233. doi:10.3390/ijms24087233
BibTeX
@article{Kumar2023,
author = {Kumar, Santosh and Sherman, Michael Y},
title = {Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {8},
pages = {7233},
doi = {10.3390/ijms24087233}
}
EUVIMED